Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Conditions:   Carcinoid Syndrome;   Carcinoid;   Carcinoid Tumor;   Carcinoid Tumor of Ileum;   Carcinoid Tumor of Cecum;   Carcinoid Syndrome Diarrhea;   Carcinoid Intestine Tumor;   Carcinoid Tumor of Liver;   Carcinoid Tumor of Pancreas
Interventions:   Drug: Randomized: 40 mg Paltusotine;   Drug: Randomized: 80 mg Paltusotine
Sponsor:   Crinetics Pharmaceuticals Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 6, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments